Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

NYU Langone Health

Collaborators

[object Object]